Hereditary multiple exostoses and solitary osteochondroma associated with growth hormone deficiency: to treat or not to treat?

Mauro Bozzola, Chiara Gertosio, Maria Gnoli, Federico Baronio, Elena Pedrini, Cristina Meazza, Luca Sangiorgi

Research output: Contribution to journalArticlepeer-review

Abstract

BACKGROUND:
Osteochondroma generally occurs as a single lesion and it is not a heritable disease. When two or more osteochondroma are present, this condition represents a genetic disorder named hereditary multiple exostoses (HME). Growth hormone deficiency (GHD) has rarely been found in HME patients and a few data about growth therapy (GH) therapy effects in development/growth of solitary or multiple exostoses have been reported.
CASE PRESENTATION:
We describe the clinical features of 2 patients (one with osteochondroma and one with HME) evaluated before and after GH therapy. In the first patient, the single osteochondroma was noticed after the start of treatment; the other patient showed no evidence of significant increase in size or number of lesions related to GH therapy.
CONCLUSION:
It is necessary to investigate GH secretion in patients with osteochondroma or HME and short stature because they could benefit from GH replacement therapy. Moreover, careful clinical and imaging follow-up of exostoses is mandatory.
Original languageEnglish
Pages (from-to)1-6
Number of pages6
JournalItalian Journal of Pediatrics
Publication statusPublished - Aug 2015

Fingerprint Dive into the research topics of 'Hereditary multiple exostoses and solitary osteochondroma associated with growth hormone deficiency: to treat or not to treat?'. Together they form a unique fingerprint.

Cite this